August 23, 2022
Advanced cancer treatment often involves combining multiple drugs. But with a huge number of possible combinations, it is difficult to know which mix might work best for each patient. Here, our Curious Dr. George asks two leaders to describe how the company First Ascent Biomedical is addressing this challenge. Curious Dr. George: The U.S. Food and Drug Administration (FDA) has approved many thousands of… Read more »
- July 8, 2022
- July 1, 2022
June 10, 2022
NCI Overview of Uterine Cancer BookmarkGeorge Lundberg, MD
The National Cancer Institute provides this online overview of uterine cancer that is up-to date, comprehensive, and written specifically for patients.
- April 2, 2020
March 7, 2019
Researchers Tap Genomic Technology to Develop Personalized Treatments for Pediatric Glioma BookmarkEmma Shtivelman, PhD
“Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.
“Sabine Mueller, MD, PhD, adjunct associate professor of neurology, pediatrics and neurosurgery at University of California, San Francisco, and colleagues aim to treat as many as 44 children and young adults with this disease.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
- March 5, 2019
- February 3, 2017
September 9, 2015
Emma Shtivelman, PhD
These days, it seems that I write mostly about immune checkpoint blockade drugs, or some other new immunotherapy treatment for cancer. This post is no different—it covers PD-L1, a protein that is at the center of clinical decisions for selecting patients who are likely to benefit from treatment with an anti-PD-1 or anti-PD-L1 drug.
August 13, 2015
Emma Shtivelman, PhD
Of all cancer types, melanoma is the most investigated in terms of its potential to be treated through immune system-based approaches. More immunotherapy drugs are approved for melanoma than for any other type of cancer, and more are in development. Recent additions to the immunotherapy arsenal are the ‘anti-PD-1’ immune checkpoint blockade drugs pembrolizumab (Keytruda) and nivolumab (Opdivo).